Literature DB >> 25789271

Significance of a common variant in the CDKAL1 gene with susceptibility to type 2 diabetes mellitus in Iranian population.

Yaser Mansoori1, Abdolreza Daraei2, Mohammad Mehdi Naghizadeh1, Rasoul Salehi3.   

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a worldwide problem that threatens the public health and economies of all countries. A multifactorial etiology and interaction between environmental factors and genetic components are responsible for triggering and progression of T2DM. Recently, rs7754840 single nucleotide polymorphism (SNP) in the CDKAL1 gene was reported to be associated with T2DM in various populations. However, due to inconsistent results in various populations about the association of rs7754840 with T2DM, and lack of information in the Iranian population, we have evaluated its association with T2DM in a subset of the Iranian population from Isfahan province, central part of Iran.
MATERIALS AND METHODS: The study included 140 patients and 140 controls selected based on the World Health Organization guidelines. Genomic DNA was extracted from blood samples and the rs7754840 SNP was genotyped using a polymerase chain reaction-restriction fragment length polymorphism assay with specific primers and restriction enzyme (Ac1I).
RESULTS: The frequency of the C allele in the cases was higher than that in the controls (72.9% vs. 65%; P = 0.045). Using logistic regression analysis, we found a significant risk association of CC genotype with T2DM susceptibility (OR = 2.319, 95% CI = 1.436-3.744, P = 0.001). Furthermore, compared with the CC genotype, individuals with the GC genotype had a lower risk (protective association) of developing T2DM (OR = 0.332, 95% CI = 0.202-0.547, P < 0.001).
CONCLUSIONS: We confirmed that there is a significant risk association between rs7754840 polymorphism and development of T2DM in a subset of the Iranian population from Isfahan province.

Entities:  

Keywords:  CDKAL1 gene; single nucleotide polymorphism; type 2 diabetes mellitus

Year:  2015        PMID: 25789271      PMCID: PMC4358034          DOI: 10.4103/2277-9175.151256

Source DB:  PubMed          Journal:  Adv Biomed Res        ISSN: 2277-9175


INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a global public health crisis that threatens the economies of all nations, and its prevalence continues to increase in many countries, including Iran.[12] Although the exact underlying molecular mechanisms of T2DM development have not been fully revealed, a mixture of various genetic and environmental elements is deliberated to be involved in pathogenesis of the disease.[34] In addition to the important contribution of environmental factors, including dietary patterns and lifestyle, genetic determinants also play a major role in T2DM susceptibility.[35] In recent years, many genes associated with T2DM were recognized by genome-wide association studies (GWAS).[67891011] From these, cyclin-dependent kinase 5 regulatory subunit-associated protein 1 - like 1 (CDKAL1) gene was newly known as a predisposition gene for T2DM through GWAS in white European and Asian populations.[111213141516] This gene encodes CDKAL1 protein that might influence the action of the CDK5 protein, which promotes insulin production, and may impact on other functions in the insulin-producing β-cells of the pancreas gland.[1718] Moreover, it is supposed that elevated activity of CDK5 in the absence of CDKAL1 has a role in the pathophysiology of β-cell defect.[171920] However, precise molecular mechanisms of susceptibility to T2DM by interactions between these proteins are not yet clear.[2021] Replication studies reproducibly evaluated the association between T2DM and rs7754840 SNP within the CDKAL1 gene in multiple populations of Europe and Asian.[1213151622232425262728] Most of the studies confirmed this significant association.[1213151622252629] However, some studies failed to detect a significant association, suggesting variability in the contribution of this SNP to the risk of T2DM in different ethnic tribes.[2728] In spite of the regular associations among Europeans and Asians, the contribution of this genetic variant in some ethnic groups such as Iran is not determined. Therefore, we conducted a replication study of candidate rs7754840 SNP in CDKAL1 gene in a subset of the Iranian population from the Isfahan province in relation to the T2DM.

MATERIALS AND METHODS

Study population

A total of 280 individuals, including 140 T2DM patients and 140 normal controls, were involved in the current study. Diabetes was defined according to the World Health Organization criteria (fasting plasma glucose 7.0 mmol/L and/or 2-h plasma glucose ≥ 11.1 mmol/L) and only confirmed cases were included in the study. We also randomly selected and examined 140 control subjects from the general population who were enrolled from an annual health check directed at the same center (31 men and 109 women; age 48.40 ± 12.31 years; fasting plasma glucose 90.40 ± 6.17 mg/dL; BMI 26.3 ± 1.8 kg/m2; Table 1). For control individuals, lack of history of diabetes in the subjects and among their first-degree relatives was carefully monitored. Informed consent was obtained from all participants by a standard questionnaire and the Ethics Committee of the Isfahan University of Medical Sciences approved this study.
Table 1

Demographic parameters in the cases and controls

Demographic parameters in the cases and controls

SNP genotyping

Peripheral blood samples of participants were collected and then genomic DNA was isolated from whole blood samples by the DNG-plus DNA extraction kit (Cinnagen, Iran) according to the manufacturer's instructions. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). PCR was performed using the following primers: Forward 5’-GAGTTTCAAATTGTCCAG-3’ and reverse 5’-TCTGTTATTGACTGAGGTAT-3’. The PCR cycling conditions were adjusted as follows: Denaturation at 95°C for 6 min followed by 30 cycles at 94°C for 50 s, 57°C for 50 s and 72°C for 50 s, followed by a final extension at 72°C for 5 min. The amplified products were separated by electrophoresis through 2% agarose gel stained with ethidium bromide. For RFLP of rs7754840 polymorphism, the PCR products were digested with the AclI restriction endonuclease (Fermentas, Lithuania) for 3 h at 37°C. Following digestion, the appearance of two bands of 112 bp and 80 bp was indicative of the CC genotype, whereas 192 bp digestion products were indicative of the GG genotype. Also, when heterozygous genotypes exist, three bands were observed: 192 bp, 112 bp and 80 bp [Figure 1]. For confirmation of the determined genotype by PCR-RFLP, we performed direct sequencing on 10% of the randomly selected samples.
Figure 1

Lane 1 (L): DNA ladder, lanes 2; (C=Control) PCR product (undigested); lane 3; GC Heterozygous, lanes 4 and 6; GG genotypes, lane 5; CC Homozygous

Lane 1 (L): DNA ladder, lanes 2; (C=Control) PCR product (undigested); lane 3; GC Heterozygous, lanes 4 and 6; GG genotypes, lane 5; CC Homozygous

Statistical analyses

Statistical analyses were achieved using SPSS for Windows software (version 18.0; SPSS, Chicago, IL, USA). The allele and genotype frequencies were tested for Hardy-Weinberg equilibrium using the x2test. Logistic regression analysis was accomplished to calculate distributions and risk allele/genotype-specific odds ratios (ORs), 95% confidential intervals (CIs) and analogous P values after adjustment for gender, age and body mass index (BMI) as covariates between cases. All continuous variables were expressed as the mean ± standard deviation (SD). Student's t test was used to compare the continuous variables between the T2DM and non-diabetic control groups. Pearson's v2 test was used to evaluate the difference in the prevalence of T2DM among the genotypes.

RESULTS

Information of clinical and biochemical characteristics of the participants are shown in Table 1. The mean age, BMI and fasting plasma glucose (FPG) level were 51.15 ± 8.97 years, 27 ± 2.4 kg/m2 and 161.44 ± 62.07 mg/dL for the diabetic patients, respectively, and 48.40 ± 12.31 years, 26.3 ± 1.8 kg/m2 and 90.40 ± 6.17 mg/dL for the controls, respectively. A higher proportion of females than males were observed in the case (60.7% vs. 39.3%) and control groups (77.9% vs. 22.1%), which may be as a result of a contribution bias in our population. The association results of genotype and allele frequencies of the T2DM-susceptibility rs7754840 variant in patients and control individuals is shown in Table 2. According to our results, frequencies of the CC, CG and GG genotypes of rs7754840 were 38.6, 52.9 and 8.6% in controls and 59.3, 27.1 and 13.6% in cases, respectively. Among these three genotypes of the rs7754840 SNP in the CDKAL1 gene, CC was found to be meaningfully associated with an increased risk [OR = 2.921 (95% CI 1.789-4.771), P = <0.001] of T2DM in our population. Also, the frequency of the C allele in cases (72.9%) was more than that in the healthy control group (27.1%), acting as a risk allele [OR = 2.319 (95% CI 1.436-3.744); P = 0.001]. The risk allele (C allele) was the same direction as the previous studies, but this risk allele was the minor allele in Asian groups. Beside this, we found that compared with the CC genotype (as risk genotype), individuals with the GC heterozygote genotype had a lower risk and protective association to develop T2DM (as protective genotype; OR = 0.332, 95% CI = 0.202–0.547, P < 0.001). We then tested the association between genotypes and T2DM-related traits such as gender, age (under and over 50 years) and BMI (under and over 25 kg/m2) to examine whether these genotypes conferred a risk of T2DM through their effects on any of these traits [Table 3]. We found consistent results for all variables except for individuals with age under 50 years who showed no significant association (OR = 1.759, 95% CI = 0.882-3.507, P = 0.108) and males who had a marginal association.
Table 2

Allele and genotype distribution of rs7754840 SNP in cases and controls and its association with T2DM

Table 3

Stratification analysis of rs7754840 SNP genotype frequency in cases and controls based on T2DM-related traits

Allele and genotype distribution of rs7754840 SNP in cases and controls and its association with T2DM Stratification analysis of rs7754840 SNP genotype frequency in cases and controls based on T2DM-related traits

DISCUSSION

Recent GWAS studies have recognized rs7754840 SNP in the CDKAL1 gene associated with T2DM in white Europeans and Asians.[1011273031] The association between CDKAL1 rs7754840 SNP and T2DM has been broadly studied in different populations.[121315162224272932] Most replication studies proved a significant relationship,[131622242629] nevertheless, some studies failed to detect a noteworthy association,[2728] proposing variability in the impact of this polymorphism to conferring the risk of T2DM in various populations. To explore this issue, we performed the present replication study to evaluate and replicate the association of rs7754840 SNP within CDKAL1 gene in a subset of Iranians from Isfahan province. Our results showed that the carriers of C allele and CC homozygous genotypes of the rs7754840 SNP had an increased risk and were more likely to develop T2DM compared with those with GG homozygous and GC heterozygous genotypes (adjusted OR = 2.921 [95% CI 1.789-4.771], P = <0.001). Consistent with our study, a significant association between C allele and CC genotypes of this SNP and T2DM was seen in most ethnic groups in the European[1216] and Asian populations.[1315] Among these, the CC genotype was significantly associated with T2DM in the Finnish,[18] Ashkenazi,[33] Han Chinese people from Hong Kong,[34] Korean[25] and Japanese populations,[2435] although a marginal relationship was found (P = 0.05 and P = 0.076) in the two Japanese studies.[3536] Also, in spite of the significant results from our work and the aforementioned studies, some studies failed to find any association; for instance, no statistically significant association of the rs7754840 variant with T2DM was reported in two studies from Europe,[933] Indian Sikhs[37] and Pima Indians.[28] These inconsistencies findings propose that rs7754840 SNP might has an even more important interaction in diabetes susceptibility basis on different genetic background of diverse ethnic groups, lifestyles and environmental variables in different populations. To the best of our knowledge, the present work is the first replication study to evaluate the association of CDKAL1 and T2DM-susceptibility in the Iranian population. In addition, for this SNP, the C risk allele was a major allele in our population, consistent with former reports in European populations,[15] while the C allele was shown as a minor allele in the Asian groups.[12] Therefore, these variances might reveal the differences in the outcomes for the association of rs7754840 SNP in the CDKAL1 gene with T2DM. Ethnic differences in risk allele frequencies for rs7754840 SNP may lead to differences in the attributable risk allele and thus alter its effect on different populations. Interestingly, we also detected a novel significant association finding in our study: Compared with the CC genotype (as risk genotype), individuals with the GC heterozygote genotype had a lower risk and protective association to develop T2DM (as protective genotype), suggesting that each genotype has a distinctive effect related to T2DM; however, more replication studies and meta-analyses are required for the evaluation of this genotype-specific effect in different populations. Furthermore, when we performed stratification analysis on the basis of T2DM-related traits such as gender, age (under and over 50 years) and BMI status (under and over 25 kg/m2) regarding the CC risk genotype, another association was detected. The CC genotype only in subgroups of over 50 years is a risk genotype, and, in the subgroup of under 50 years, was not related to T2DM susceptibility. This suggests that genetic susceptibility caused by this genetic variant in our population is often associated with a late age of onset (age specific) and may play a more important role in the development of T2DM among older patients in the Iranian population. This finding is also consistent with this fact that multifactorial diseases such as diabetes to be revealed with elevated age due to the interaction between genetic background and environmental factors. In conclusion, our finding confirms the association between rs7754840 polymorphism in the CDKAL1 gene and sporadic T2DM risk and also the GC heterozygote genotype of the polymorphism is associated with reduced risk (protective effect) of T2DM development compared with the CC genotype. Furthermore, our study suggests an association between the CC genotype of the rs7754840 polymorphism and people with late-onset T2DM. This genetic susceptibility may be a valuable marker for differentiating people with an elevated risk of T2DM, who could then be subjected to a further careful or earlier routine screening for T2DM. Also, to further confirm this association, additional studies are needed to elucidate the exact functional mechanism of this variant.
  36 in total

1.  Single-nucleotide polymorphism rs7754840 of CDKAL1 is associated with impaired insulin secretion in nondiabetic offspring of type 2 diabetic subjects and in a large sample of men with normal glucose tolerance.

Authors:  Alena Stancáková; Jussi Pihlajamäki; Johanna Kuusisto; Norbert Stefan; Andreas Fritsche; Hans Häring; Francesco Andreozzi; Elena Succurro; Giorgio Sesti; Trine Welløv Boesgaard; Torben Hansen; Oluf Pedersen; Per Anders Jansson; Ann Hammarstedt; Ulf Smith; Markku Laakso
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

2.  Implication of genetic variants near SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, FTO, TCF2, KCNQ1, and WFS1 in type 2 diabetes in a Chinese population.

Authors:  Xueyao Han; Yingying Luo; Qian Ren; Xiuying Zhang; Fang Wang; Xiuqin Sun; Xianghai Zhou; Linong Ji
Journal:  BMC Med Genet       Date:  2010-05-28       Impact factor: 2.103

3.  Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.

Authors:  Richa Saxena; Benjamin F Voight; Valeriya Lyssenko; Noël P Burtt; Paul I W de Bakker; Hong Chen; Jeffrey J Roix; Sekar Kathiresan; Joel N Hirschhorn; Mark J Daly; Thomas E Hughes; Leif Groop; David Altshuler; Peter Almgren; Jose C Florez; Joanne Meyer; Kristin Ardlie; Kristina Bengtsson Boström; Bo Isomaa; Guillaume Lettre; Ulf Lindblad; Helen N Lyon; Olle Melander; Christopher Newton-Cheh; Peter Nilsson; Marju Orho-Melander; Lennart Råstam; Elizabeth K Speliotes; Marja-Riitta Taskinen; Tiinamaija Tuomi; Candace Guiducci; Anna Berglund; Joyce Carlson; Lauren Gianniny; Rachel Hackett; Liselotte Hall; Johan Holmkvist; Esa Laurila; Marketa Sjögren; Maria Sterner; Aarti Surti; Margareta Svensson; Malin Svensson; Ryan Tewhey; Brendan Blumenstiel; Melissa Parkin; Matthew Defelice; Rachel Barry; Wendy Brodeur; Jody Camarata; Nancy Chia; Mary Fava; John Gibbons; Bob Handsaker; Claire Healy; Kieu Nguyen; Casey Gates; Carrie Sougnez; Diane Gage; Marcia Nizzari; Stacey B Gabriel; Gung-Wei Chirn; Qicheng Ma; Hemang Parikh; Delwood Richardson; Darrell Ricke; Shaun Purcell
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

Review 4.  Genome-wide association studies provide new insights into type 2 diabetes aetiology.

Authors:  Timothy M Frayling
Journal:  Nat Rev Genet       Date:  2007-09       Impact factor: 53.242

5.  Replication study of candidate genes associated with type 2 diabetes based on genome-wide screening.

Authors:  Yasuharu Tabara; Haruhiko Osawa; Ryuichi Kawamoto; Hiroshi Onuma; Ikki Shimizu; Tetsuro Miki; Katsuhiko Kohara; Hideichi Makino
Journal:  Diabetes       Date:  2008-11-25       Impact factor: 9.461

6.  Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes.

Authors:  Eleftheria Zeggini; Michael N Weedon; Cecilia M Lindgren; Timothy M Frayling; Katherine S Elliott; Hana Lango; Nicholas J Timpson; John R B Perry; Nigel W Rayner; Rachel M Freathy; Jeffrey C Barrett; Beverley Shields; Andrew P Morris; Sian Ellard; Christopher J Groves; Lorna W Harries; Jonathan L Marchini; Katharine R Owen; Beatrice Knight; Lon R Cardon; Mark Walker; Graham A Hitman; Andrew D Morris; Alex S F Doney; Mark I McCarthy; Andrew T Hattersley
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

7.  Association analysis of variation in/near FTO, CDKAL1, SLC30A8, HHEX, EXT2, IGF2BP2, LOC387761, and CDKN2B with type 2 diabetes and related quantitative traits in Pima Indians.

Authors:  Rong Rong; Robert L Hanson; Daniel Ortiz; Christopher Wiedrich; Sayuko Kobes; William C Knowler; Clifton Bogardus; Leslie J Baier
Journal:  Diabetes       Date:  2008-11-13       Impact factor: 9.461

8.  Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians.

Authors:  Maggie C Y Ng; Kyong Soo Park; Bermseok Oh; Claudia H T Tam; Young Min Cho; Hyoung Doo Shin; Vincent K L Lam; Ronald C W Ma; Wing Yee So; Yoon Shin Cho; Hyung-Lae Kim; Hong Kyu Lee; Juliana C N Chan; Nam H Cho
Journal:  Diabetes       Date:  2008-05-09       Impact factor: 9.461

9.  Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk.

Authors:  Dharambir K Sanghera; Lyda Ortega; Shizhong Han; Jairup Singh; Sarju K Ralhan; Gurpreet S Wander; Narinder K Mehra; John J Mulvihill; Robert E Ferrell; Swapan K Nath; Mohammed I Kamboh
Journal:  BMC Med Genet       Date:  2008-07-03       Impact factor: 2.103

10.  Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value.

Authors:  Stéphane Cauchi; David Meyre; Emmanuelle Durand; Christine Proença; Michel Marre; Samy Hadjadj; Hélène Choquet; Franck De Graeve; Stefan Gaget; Frederic Allegaert; Jérôme Delplanque; Marshall Alan Permutt; Jon Wasson; Ilana Blech; Guillaume Charpentier; Beverley Balkau; Anne-Claire Vergnaud; Sébastien Czernichow; Wolfgang Patsch; Mohamed Chikri; Benjamin Glaser; Robert Sladek; Philippe Froguel
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

View more
  6 in total

1.  Association of rs7754840 G/C polymorphisms in CDKAL1 with type 2 diabetes: a meta-analysis of 70141 subjects.

Authors:  Muhadasi Tuerxunyiming; Patamu Mohemaiti; Hamulati Wufuer; Awaguli Tuheti
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Comparative study of serum 8-hydroxydeoxy-guanosine levels among healthy offspring of diabetic and non-diabetic parents.

Authors:  Marghoob Hasan; Abdelmarouf Hassan Mohieldein; Fahad Rahib Almutairi
Journal:  Int J Health Sci (Qassim)       Date:  2017 Jul-Sep

3.  Association Between Single Nucleotide Polymorphisms in CDKAL1 and HHEX and Type 2 Diabetes in Chinese Population.

Authors:  Chuanyin Li; Keyu Shen; Man Yang; Ying Yang; Wenyu Tao; Siqi He; Li Shi; Yufeng Yao; Yiping Li
Journal:  Diabetes Metab Syndr Obes       Date:  2021-01-05       Impact factor: 3.168

4.  CDKAL1 gene rs7756992 A/G and rs7754840 G/C polymorphisms are associated with gestational diabetes mellitus in a sample of Bangladeshi population: implication for future T2DM prophylaxis.

Authors:  U S Mahzabin Amin; Nahid Parvez; Tahia Anan Rahman; Md Rakibul Hasan; Keshob Chandra Das; Sharmin Jahan; Muhammad Abul Hasanat; Zeba I Seraj; Md Salimullah
Journal:  Diabetol Metab Syndr       Date:  2022-01-28       Impact factor: 3.320

5.  Erchen Decoction Prevents High-Fat Diet Induced Metabolic Disorders in C57BL/6 Mice.

Authors:  Bi-Zhen Gao; Ji-Cheng Chen; Ling-Hong Liao; Jia-Qi Xu; Xiao-Feng Lin; Shan-Shan Ding
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-04       Impact factor: 2.629

6.  Pharmacogenomics of Sulfonylureas Response in Relation to rs7754840 Polymorphisms in Cyclin-Dependent Kinase 5 Regulatory Subunit-associated Protein 1-like (CDKAL1) Gene in Iranian Type 2 Diabetes Patients.

Authors:  Goljahan Soltani; Zahra Hatefi; Ahmad Reza Salehi; Sharifeh Khosravi; Moosa Rahimi Ghiasi; Keimer Teke; Ashraf Aminorroaya; Rasoul Salehi
Journal:  Adv Biomed Res       Date:  2018-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.